Pfizer Will Separate Commercial Operations into Segments and 2 Other Hot Stocks to Watch

Pfizer Inc. (NYSE:PFE): Current price $29.67

On Monday, the number one domestic drug producer announced that it will internally separate its commercial operations into three business segments, among which include two divisions that sell patent-protected branded drugs, and one that sells generic medicines. Pfizer said that the changes will become operational in January in countries that do not require a consultation with labor unions. Earlier in 2013, the company said it would begin separately looking at the finances and marketing of its patent-protected drug unit, which it calls its “innovative” business, and its generic operation, its “value” business — a move possibly preceding the selling off of the generic business in the future.


Omnicom Group Inc. (NYSE:OMC): Current price $65.67

Omnicom and Publicis announced Sunday that they will merge to form the largest advertising group on the planet, worth $35.1 billion, a link-up that could prompt competitors to make deals in order to keep up with large innovation from tech and the Internet. Further, the firms said that the transaction is a merger of equals, and will “bring the necessary scale and investment firepower to cope with rapid changes wrought by technology on the advertising business.” Publicis Chief Executive Maurice Levy said that “This is a new company for a new world. It will be able to face the exponential development of new internet giants like Facebook and Google, changing consumer behavior, the explosion of big data, as well as handle the blurring of roles of all the players in the market.”


Sirius XM Radio Inc. (NASDAQ:SIRI): Current price $3.75

Sirius will offer $600 million of Senior Notes due 2021 to qualified institutional buyers, through Rule 144A under the Securities Act of 1933, as amended, and overseas in compliance with Regulation S of the Securities Act. The company intends to use the net proceeds, together with cash on hand, to redeem its outstanding 8.75 percent Senior Notes, due 2015.


Don’t Miss: FDA Is Restricting This Johnson & Johnson Drug.